PK PD Analysis Services and Non-Compartmental Analysis in Validated Phoenix WinNonlin, by PhDs at 20+ Year, FDA-Inspected US Lab

In linear pharmacokinetics, systemic concentration over time data fits a one-compartment model. Typically, the concentration data may be matched to a single or multi-compartment PK model to help interpret pharmacokinetic equations and make therapeutic decisions. Most pharmacokinetics of drugs are performed without specifying the applicable mathematical model (non-compartmental analysis). One primary characteristic of linear models is that the change in concentration over time is constant. Thus, the compound’s half-life is constant and area under curve (AUC) pharmacokinetics increases linearly with dosage regardless of the body’s drug level. Therefore, doubling the dose will result in doubling the AUC, or administering half the dose twice per day will result in the same AUC as administering the total dose once per day. Contrastingly, non-linear pharmacokinetic models result from saturable behavior in the absorption, distribution, metabolism, or excretion of the compound. Here, saturable metabolism or excretion results in higher than dose-proportional increases in AUC pharmacokinetics with dosage, and saturable absorption results in lower than dose-proportional increases in AUC pharmacokinetics with dosage. In either case, the validity of PK parameters depends on the data’s quality entered into the model. Thus, dosing and sample collection must be precisely timed, and analytical methods must be sensitive and specific. Pharmacokinetics of drugs must be weighted appropriately to avoid bias due to the increased probability of errors at drug concentrations near the assay’s detection limit. Results obtained using a specific pharmacokinetic model should be compared to those using noncompartmental methods.

Area under curve (AUC) is calculated for the concentration vs. time curve by totaling trapezoidal areas between each measured time point. We can use various mathematical rules for these calculations based on linear or logarithmic transformations. One simple AUC pharmacokinetics calculation uses the linear trapezoidal rule with the equation Atrap = ((c1 + c2) / 2) / (t2 – t1). Here, Atrap is the trapezoidal area, and c1 and c2 are the measured concentrations at time points t1 and t2. AUC is the integration or summation of all such areas throughout the measured time points. We can extrapolate AUC in pharmacokinetics to infinity by adding the final triangle area created by the terminal extrapolation of the elimination phase to the time axis. Our scientists calculate and interpret your drug’s AUC figures to understand total exposure following any pharmacokinetic modeling.

Systemic Clearance (CL or CLs) in pharmacokinetics represents the rate at which a drug gets removed from the bloodstream. Clearance is determined from non-compartmental analysis following IV dosing. It represents total additive clearance from all potential clearing organs (e.g., liver, kidneys, etc.). We measure clearance values in units of volume/time and think of it as a proportionality constant between drug concentration and elimination rate. The non-compartmental pharmacokinetic equation for clearance is CL = Dose/AUC.

Tmax in pharmacokinetics represents the time after dosing when a compound reaches its maximum concentration in the bloodstream following extravascular dosing. Usually, the lower rates of absorption result in extended Tmax values.

Cmax in pharmacokinetics is the maximum observed concentration during a PK study. There is no mathematical calculation for the determination of Cmax. Therefore, we must design PK studies appropriately to capture Cmax and Tmax accurately.

Following repeated drug administrations, the systemic concentrations in the body reach an equilibrium where the rate of drug intake equals the rate of excretion. This equilibrium is described as steady-state. Typically, it takes administrations over approximately five half-lives of the drug to reach steady-state independent of dose level and dosing interval. We can calculate steady-state concentration (Css) by dividing the total exposure over the dosing interval (AUClast) by the interval time (Tlast).

T1/2 in pharmacokinetics, i.e., elimination half-life, represents the time it takes to clear half of the compound’s concentration from systemic circulation during the log-linear elimination phase. Even as elimination half-life can be calculated for any dose route, it is best represented for a compound following an IV dose given the absorption component is bypassed with direct systemic administration. IV bolus curves for most drugs are biphasic, including a steep early phase representative of compound distribution to tissues, metabolism, and excretion. Once tissue distribution is equilibrated, the second phase of the curve represents metabolism and excretion. Points in this log-linear elimination phase are selected and used to determine the curve slope (m). The elimination rate constant (λz, k, or kel) is calculated from the slope as λz = 2.303 x m. Then, we calculate elimination half-life (t½) as 0.693 / λz. For reliability, the half-life calculation should be performed with a minimum of three terminal points in the λz range and have a determination coefficient (R2) of at least 0.85.

Volume of Distribution in pharmacokinetics is typically abbreviated Vd, Vz, or Varea. Vd in pharmacokinetics reflects the reversible uptake of drugs by tissues from the blood. It is thought of as a fictitious volume that a drug occupies in the body as a uniform sack relative to the drug concentration in blood. Large Volumes of Distribution indicates more significant levels of the drug, reaching tissues relative to measured plasma concentrations and can show the compound’s potential for achieving the desired target. We calculate Vd in pharmacokinetics by dividing the measured Clearance (CL) with the elimination rate constant (λz). Volumes of distribution can be calculated following IV doses. Similarly, the apparent Volume of Distribution (Vd/F) may be determined for extravascular doses and includes a bioavailability correction factor to account for the compound’s absorption. Volume of distribution at steady-state (Vss) is another useful PK parameter for predicting tissue distribution and is calculated as mean residence time (MRT) times clearance (CL) following IV dosing.

PD is the measured effect: a biomarker, a cytokine, receptor occupancy, something the drug does that a number can capture. PK alone says the body saw the drug; PK/PD says the drug did something at that exposure, which is what dose selection actually rests on. Not every study needs it, but when yours does, the PD endpoint is an assay we run too, so the exposure and the effect come off the same accession instead of from two vendors.

Yes, standalone NCA on somebody else’s data is routine here. Send the concentrations and the dosing and sampling records; the analysis and report come back in your format. Twenty years of running the assays themselves means an odd number gets recognized for what it is, a dilution issue, a below-quantitation artifact, real biology, rather than passed through a statistician who never met the assay.

Concentration-time data with units, the dosing record, dose levels, routes and times, the sampling schedule as executed rather than as planned, and any protocol definitions for parameters your report must include. Clean datasets return in one to two weeks, and gaps get flagged to you before they become assumptions.

Yes, prepared alongside the analysis rather than bolted on afterward: SEND for nonclinical studies, SDTM for clinical work, built so your submission team receives tables that drop in rather than a conversion project. Most labs treat this as someone else’s problem; here it is part of the deliverable.

Non-compartmental analysis is the regulatory workhorse: assumption-light, standardized, and what most submissions expect for exposure parameters. Compartmental fitting earns its complexity when you need to simulate unstudied regimens, interpolate between doses, or feed population PK. Practical answer: NCA first, model when a question demands it; one- and two-compartment fitting runs in house and population PK runs through our modeling partner.

Phoenix WinNonlin, in a validated installation, the industry standard regulators read fluently. Validation of the install, not just the vendor’s word, is part of why the numbers stand in an eCTD without argument. SEND and SDTM outputs are prepared alongside the analysis in the same environment.